SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after reporting substantial year-over-year revenue growth and expanded global approvals for its ANKTIVA cancer therapies in new markets and indications like lung cancer. The community is buzzing with talk of a potential short squeeze, encouraging buying dips, and anticipating significant long-term upside as the company broadens its global commercial footprint.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following FDA approval for BYSANTI in bipolar I disorder and schizophrenia, a New Chemical Entity with patent protection extending to 2044. The community is actively discussing the company's significant undervaluation, anticipating a major re-rating or potential buyout interest from big pharma, especially with its recent second drug approval and a robust pipeline.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after releasing positive Phase 2 trial data for its lead drug sonelokimab in axial spondyloarthritis, showing high efficacy and signs of disease modification ahead of its Investor Day. The community views this, coupled with a strong cash position and high short interest, as a significant re-rating catalyst, anticipating a substantial surge and potential for best-in-class market positioning.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending due to a sector-wide sell-off following Anthropic's Claude Code Security announcement, with community members divided on whether AI threatens CRWD's core endpoint and cloud security or reinforces the need for its advanced, AI-native platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing a significant downturn after its CagriSema weight-loss drug demonstrated slightly lower efficacy than a competitor in a recent trial, prompting community discussion on whether the market's reaction is an overcorrection despite NVO's strong financial position and other successful products.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna (MRNA) is trending after the FDA reversed its initial refusal and agreed to review the company's seasonal flu vaccine application, igniting a significant short squeeze and renewed optimism for its broader mRNA pipeline, particularly in oncology and other respiratory diseases.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as a top contender in the obesity drug market after a competitor's recent trial results underscored the potential superiority and tolerability of Viking's dual GLP-1/GIP agonist, VK2735. The community is actively discussing massive short interest, the advancing oral program, and intense speculation about an imminent buyout or significant partnership with a major pharmaceutical company seeking a leading position in the rapidly expanding metabolic space.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx Inc. is trending sharply higher after Gilead Sciences announced a definitive agreement to acquire the company for $7.8 billion, including a substantial premium per share. The community is actively discussing this major buyout as a validation of Arcellx's promising CAR T therapy, anito-cel for multiple myeloma, and a significant event that highlights acquisition potential within the biotech sector.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

Recent IPO AIDX is trending due to extreme volatility and significant community debate, with some labeling it a 'pump and dump' anticipating further declines while others expect a major bounce, all within a broader sector experiencing pressure.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is trending as the market reacts to fears that Anthropic's new AI-powered Claude Code Security tool could disrupt its business, causing a significant sector-wide sell-off. However, many in the community contend that Zscaler's real-time network and access control are distinct from static code analysis, arguing it will ultimately benefit from the rising complexity of AI-driven cyber threats.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets Stock futures slumped after Trump's weekend tariff tantrum added uncertainty to American trade policy and was another blow to bullish...

Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug

Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer.read more...

Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more

These are the stocks posting the largest moves in premarket trading...

ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Arcellx, Inc. (NASDAQ: ACLX) to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of...

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion...

Shares of Arcellx Inc (ACLX) surged nearly 80% in pre-market trading on Monday after Gilead Sciences, Inc. (GILD) announced an agreement to acquire Arcellx in a deal worth around $7.8 billion.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/ACLX">ACLX shares</a> will hit an all-time high. Meanwhile, <a href="https://stocktwits.com/symbol/GILD">GILD shares</a> traded 1.2% lower in pre-market trading.<h2 class="st-heading-2">Gilead Sciences To Acquire Arcellx</h2>Under the agreement, Gilead will pay $115 per share in cash plus a $5 contingent value right (CVR) tied to future sales milestones. The offer is a 68% premium to Arcellx’s 30-day average share price as of Feb. 20, 2026.Gilead, which already owns roughly 11.5% of Arcellx, will launch a tender offer for the remaining shares. The deal is expected to close in the second quarter of 2026.The acquisition is projected to boost Gilead’s earnings per share starting in 2028, following potential U.S. Food and&nbsp;Drug&nbsp;Administration (FDA) approval of anito-cel, a treatment for multiple myeloma, a type of blood cancer.Get updates to this developing story on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did ACLX Stock Surge 80% In Pre-Market Today?

Shares of Arcellx Inc (ACLX) surged nearly 80% in pre-market trading on Monday after Gilead Sciences, Inc. (GILD) announced an agreement to acquire Arcellx in a deal worth around $7.8 billion.

Equity

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value...

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

Key PointsPerceptive Advisors sold 1,002,282 Arcellx shares in the fourth quarter; the estimated trade size was $79.96 million based on quarterly average pricing...

78,589 Shares in Arcellx, Inc. $ACLX Acquired by Monaco Asset Management SAM

Monaco Asset Management SAM acquired a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm...

Arcellx (ACLX) Expected to Announce Earnings on Thursday

Arcellx (NASDAQ:ACLX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

The biotech firm surged over 78% after Gilead Sciences announced its definitive agreement to acquire the company for $115 per share, valuing the deal at $7.8 billion.

The significant acquisition has fueled speculation on potential follow-up deals, sparking a broad rally and "sympathy plays" in the wider biotechnology sector.

Many long-term investors are celebrating substantial profits and unexpected "miracle escapes" as the acquisition price provides a significant premium.

Current Price	$64.11
Prev Close	$66.53
Open	$66.73
Dividend Yield	0.00%
50-Day Moving Average	$67.36
Beta	1.17
Avg. Volume	947,940.50
PE Ratio	-16.36

52-Week High	$94.07
52-Week Low	$47.86
Market Capitalization	$3.71B
EPS (Annual)	-$2.00
Price to Book	8.40
Revenue Per Employee	$662,184.05

ACLX
Arcellx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACLX News

ACLXArcellx Inc